Abstract Number: PB1121
Meeting: ISTH 2021 Congress
Background: For most people with cancer-associated thrombosis, current guidelines recommend anticoagulation, usually with low-molecular weight heparin (LMWH) or a non-vitamin K oral anticoagulant (NOAC); however, the recommended duration varies. Observational data describing the anticoagulation received by men with prostate cancer in routine clinical practice are limited.
Aims: We aimed to evaluate the type and duration of long-term anticoagulant therapy prescribed for the treatment and secondary prophylaxis of venous thromboembolism (VTE) in men with prostate cancer in Sweden.
Methods: This population-based record-linkage cohort study used data from the National Prostate Cancer Register, the Prescribed Drug Registry and the Patient Registry in Sweden. We identified men with a first VTE between 2013 and 2017 and described the type and duration of outpatient anticoagulation they received.
Results: Among 1413 included men, 96% started outpatient anticoagulant therapy within four weeks after VTE diagnosis. Almost two-thirds (64%) were prescribed parenteral anticoagulation, 31% a NOAC and 20% a VKA (men could receive >1 type of anticoagulant). Over the study period, use of parental anticoagulation declined from 83% to 53%, VKA use declined from 45% to 4%, and NOAC use increased from 5% to 51%. Men received their first prescription within 1–6 days after their recorded VTE (median of 2 days). The median duration of use was 7 months (interquartile range [IQR] 3–13). A fifth of men were dispensed ≤3 months anticoagulation, over half (57%) >6 months’ anticoagulation, and a quarter >1 year of anticoagulation. Duration was longer for pulmonary embolism (median 8 months, IQR 5–15) than for deep vein thrombosis (median 6 months, IQR 3–9).
Conclusions: Men with prostate cancer and VTE in Sweden were dispensed an average of 7 months’ anticoagulation; however, a wide range of treatment durations were observed reflecting the individualised approach to treating VTE in these heterogeneous patients.
To cite this abstract in AMA style:Balabanova Y, Farahmand B, Stattin P, Garmo H, Brobert G. A Population-Based Descriptive Study of Long-term Anticoagulation in the Treatment and Secondary Prophylaxis of Venous Thromboembolism in Men with Prostate Cancer in Sweden [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 2). https://abstracts.isth.org/abstract/a-population-based-descriptive-study-of-long-term-anticoagulation-in-the-treatment-and-secondary-prophylaxis-of-venous-thromboembolism-in-men-with-prostate-cancer-in-sweden/. Accessed December 7, 2021.
« Back to ISTH 2021 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/a-population-based-descriptive-study-of-long-term-anticoagulation-in-the-treatment-and-secondary-prophylaxis-of-venous-thromboembolism-in-men-with-prostate-cancer-in-sweden/